

One pot multi component synthetic approach towards the formation of 1,2,4-triazolo[1,5-*a*]pyrimidine analogues and their biological evaluation

Hasmukh R. Khunt, Piyush P. Pipaliya, Satish M. Ghelani, Jayesh S. Babariya, Yogesh T. Naliapara*

Department of Chemistry, Saurashtra University, Rajkot, Gujarat, India

*E-mail address: naliaparachem@yahoo.co.in

ABSTRACT

A library of functionalised 1,2,3-triazolo[1,5-*a*]pyrimidine derivatives has been synthesized by one pot multicomponent reaction. All synthesized novel compounds were characterised by ¹H NMR, IR, mass and elemental analysis. Compounds were also screened against bacterial and fungal strain.

Keywords: Triazolopyrimidine, One-pot multicomponent

1. INTRODUCTION


Fused heteroaromatic systems are often of much greater interest than the constituent monocyclic compounds. Recently, 1,2,4-triazolo[1,5-*a*]pyrimidines have aroused increasing attention from the chemical and biological viewpoints, due to their diverse pharmacological activities, such as antitumor potency [1,2] inhibition of KDR kinase [3], antifungal effect [4] and macrophage activation [5]. They have proved to be promising anticancer agents with dual mechanisms of tubulin polymerization promotion [1,2] as well as cyclin dependent kinases [2] inhibition [6].

One of the synthetic pathways to 1,2,4-triazolo[1,5-*a*]pyrimidines is based on the Biginelli like cyclocondensation of aromatic aldehydes and acetoacetic acid derivatives with aminoazoles containing a guanidine fragment. There are literary data about the synthesis of triazolopyrimidines by treatment of 5-amino-1,2,4-triazole or 5-aminotetrazole with aldehydes and ethyl acetoacetate or cyclic β -diketones [7-11]. The cyclocondensations were realized by heating of the starting materials in ethanol with catalytic amounts of hydrochloric acid under reflux conditions [7-9] or using DMF as solvent [10-11]. The use of acetoacetamides in these or similar reactions has not been described. However, the existing methods are suffered with some drawbacks, such as yield, time, product isolation.

Recognizing these facts, we have synthesised a new series of *N*-cyclohexyl-4,7-dihydro-5-isopropyl-7-aryl-[1,2,4]triazolo[1,5-*a*]pyrimidine-6-carboxamide starting from, *N*-cyclohexyl-4-methyl-3-oxo-pentanamide. The newly synthesized compounds were characterized by IR, Mass, ^1H NMR, ^{13}C NMR spectroscopy and elemental analysis. All the synthesized compounds were evaluated for their antimicrobial activity [12-15].

2. RESULT AND DISCUSSION

Initially, the reaction of *N*-cyclohexyl-4-methyl-3-oxo-pentanamide (**1**) with appropriate aldehyde (**2**) and aminoazole (**3**) was refluxed in 0.4 mL of DMF for 12-15 min. After cooling, methanol (~10 mL) was added. The reaction mixture was allowed to stand overnight and then filtered to give the solid (**Scheme 1**) affords the *N*-cyclohexyl-4,7-dihydro-5-isopropyl-7-phenyl-[1,2,4]triazolo[1,5-*a*]pyrimidine-6-carboxamide derivatives (**5a-o**) was obtained in excellent yield.



Scheme 1. Synthesis of pyrazolopyrimidine.

Table 1. Different Aldehydes used for the synthesis of pyrazolopyrimidines

Entry	R	Yield %	M.P.
5a	4-CH ₃ C ₆ H ₄	92	252-254
5b	4-ClC ₆ H ₅	91	260-263
5c	4-FC ₆ H ₅	84	248-250
5d	4-OCH ₃ C ₆ H ₅	90	245-247
5e	3-BrC ₆ H ₅	86	255-257
5f	3,4-di-OCH ₃ C ₆ H ₃	92	259-261
5g	3-ClC ₆ H ₄	90	265-267
5h	C ₆ H ₅	86	245-247

5i	4-OHC ₆ H ₅	93	242-244
5j	2-ClC ₆ H ₅	91	235-237
5k	2-CH ₃ C ₆ H ₅	88	255-257
5l	2-OHC ₆ H ₅	92	257-259
5m	3-NO ₂ C ₆ H ₅	90	260-262
5n	4-NO ₂ C ₆ H ₅	87	262-264
5o	3,5-di-OCH ₃ C ₆ H ₃	85	256-258

The structures of (**5a-o**) were established on the basis of their elemental analysis and spectral data (MS, IR, and ¹H NMR). The analytical data for **5a** revealed a molecular formula C₂₂H₂₉N₅O (*m/z* 379). The ¹H NMR spectrum revealed a doublet at $\delta = 0.95$ -1.10 ppm assigned to isopropyl-CH₃, a multiplet at $\delta = 1.17$ -1.58 ppm assigned to the – (5 x CH₂) protons, a singlet at $\delta = 2.23$ ppm assigned to the –CH₃ a multiplet at $\delta = 3.18$ -3.28 ppm assigned to the isopropyl-CH protons, a doublet at $\delta = 3.34$ -3.40 ppm assigned to the -CH protons, a singlet at $\delta = 6.25$ ppm assigned to the -CH protons, a multiplet at $\delta = 6.98$ -7.10 ppm assigned to the aromatic protons, a singlet at $\delta = 7.57$ ppm assigned to the -CH protons of triazoloring, a singlet at $\delta = 7.72$ -7.75 ppm assigned to -NH protons, a singlet at $\delta = 9.66$ ppm assigned to –CONH protons.

3. EXPERIMENTAL

Thin-layer chromatography was accomplished on 0.2 mm precoated plates of silica gel G60 F₂₅₄ (Merck). Visualization was made with UV light (254 and 365 nm) or with an iodine vapor. IR spectra were recorded on a FTIR-8400 spectrophotometer using DRS prob. ¹H (400 MHz) and ¹³C (100 MHz) NMR spectra were recorded on a Bruker AVANCE II spectrometer in CDCl₃. Chemical shifts are expressed in δ ppm downfield from TMS as an internal standard. Mass spectra were determined using direct inlet probe on a GCMS-QP 2010 mass spectrometer (Shimadzu). Solvents were evaporated with a BUCHI rotary evaporator. Melting points were measured in open capillaries and are uncorrected.

General procedure for the synthesis of substituted Triazolopyrimidines **5a-o**

A mixture of the aminoazole (0.01 mol), *N*-cyclohexyl-4-methyl-3-oxo-pentanamide (0.01 mol) and an appropriate aromatic aldehyde (0.01 mol) was refluxed in 0.4 mL of DMF for 12-15 min. After cooling, methanol (~10 mL) was added. The reaction mixture was allowed to stand overnight and then filtered to give the solid triazolopyrimidine products **5a-o**, which were crystallized from ethanol and subsequently dried in air.

3. 1. Spectroscopic data

N-cyclohexyl-4,7-dihydro-5-isopropyl-7-*p*-tolyl-[1,2,4]triazolo[1,5-*a*]pyrimidine-6-carboxamide (**PVP-5a**): white solid; *R_f* 0.64 (9:1 Chloroform : Methanol); IR (KBr): 3327,

3093, 2939, 1648, 1586, 1492, 1261, 1069 cm^{-1} ; ^1H NMR: δ 0.95-1.10 (d, 6H, 2 x $^i\text{prCH}_3$), 1.17-1.58 (m, 10H, 5 x CH_2), 2.23 (s, 1H, CH_3) 3.18-3.28 (m, 1H, $^i\text{prCH}$), 3.34-3.40 (s, 1H, CH), 6.25 (s, 1H, CH), 6.98-7.01 (d, 2H, Ar-H) 7.07-7.10 (d, 2H, Ar-H), 7.57 (s, 1H, CH) 7.72-7.75 (s, 1H, NH) 9.66 (s, 1H, CONH); ^{13}C NMR: δ 19.49, 19.74, 20.69, 24.60, 28.44, 30.52, 32.19, 47.51, 60.49, 102.81, 126.92, 128.64, 137.01, 137.63, 141.85, 148.42, 149.30, 165.30; MS (m/z): 379 (M^+); Anal. Calcd for $\text{C}_{22}\text{H}_{29}\text{N}_5\text{O}$: C, 69.63; H, 7.70; N, 18.45; Found: C, 69.58; H, 7.65; N, 18.52.

N-cyclohexyl-7-(4-fluorophenyl)-4,7-dihydro-5-isopropyl-[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxamide (PVP-5c): white solid; R_f 0.60 (9:1 Chloroform : Methanol); IR (KBr): 3300, 3215, 3093, 3051, 2933, 2674, 1662, 1593, 1437, 1297, 1076 cm^{-1} ; ^1H NMR: δ 1.009-1.114 (d, 6H, 2 x $^i\text{prCH}_3$), 1.19-1.56 (m, 10H, 5 x CH_2), 3.17-3.26 (m, 1H, $^i\text{prCH}$), 3.31-3.42 (m, 1H, CH), 6.31 (s, 1H, CH), 7.09-7.21 (m, 4H, Ar-H), 7.59 (s, 1H, CH), 7.70-7.73 (s, 1H, NH), 9.73 (s, 1H, CONH); MS (m/z): 383 (M^+); Anal. Calcd for $\text{C}_{21}\text{H}_{26}\text{FN}_5\text{O}$: C, 65.78; H, 6.83; N, 18.26; Found: C, 65.68; H, 6.75; N, 18.32.

4. ANTIMICROBIAL SCREENING OF SYNTHESIZED PYRIMIDINES

All the synthesized compounds were tested against different bacterial and fungal strains i.e. *Pseudomonas aeruginosa*, *Proteus vulgaris*, *Escherichia Coli*, *Staphylococcus aureus*, *Candida albican* for their in vitro antibacterial activity. Well Diffusion/Agar Cup Method was used and results are listed in Table 2.

Table 2. Antimicrobial Sensitivity Assay (Concentration 250/500/ 1000 $\mu\text{G/mL}$).

Sr. No.	CODE No.	<i>Pseudomonas aeruginosa</i>			<i>Proteus vulgaris</i>			<i>Escherichia coli</i>			<i>Staphylococcus aureus</i>			<i>Candida albicans</i>		
		250	500	1000	250	500	1000	250	500	1000	250	500	1000	250	500	1000
1.	5a	1.2	1.4	2	1.1	1.3	1.6	R	R	R	R	1	1.2	R	1.2	1.5
2.	5b	1.2	1.3	1.7	1.1	1.4	1.6	R	R	R	1.2	1.3	1.6	1	1.3	1.8
3.	5c	1.5	1.3	1.5	R	1.1	1.4	1.1	1.2	1.3	R	1	1.2	1.1	1.5	2
4.	5d	1.6	1.2	1.4	1	1.3	1.6	R	R	R	1.3	1.4	1.6	1.1	1.4	1.8
5.	5e	1.4	1.3	1.6	R	1.2	1.4	R	R	R	1.2	1.4	1.6	1	1.3	1.7
6.	5f	1.3	1.5	1.9	1	1.2	1.3	1.3	1.4	1.7	1.1	1.4	1.5	1.1	1.4	1.8
7.	5g	1.9	1.5	1.8	1.1	1.4	1.7	1.2	1.4	1.8	1.4	1.5	2	1.2	1.4	1.7
8.	5h	1.4	1.7	2	1.1	1.3	1.5	1.1	1.1	1.3	1.4	1.6	2	1.1	1.3	1.5
9.	5i	1.2	1.3	1.5	R	R	R	R	R	R	1.3	1.4	1.7	R	1.3	1.7
10.	5j	1.7	1.9	2	1.8	1.8	2	1.1	1.8	1.8	1.5	1.7	1.9	1.8	1.8	2

11.	5k	1.1	1.2	1.3	R	1	1.2	1.1	1.2	1.4	1.1	1.2	1.5	1.1	1.5	1.9
12.	5l	1.3	1.4	1.9	1.3	1.7	2.1	1.2	1.5	2	1.1	1.5	1.9	1.1	1.4	1.6
13.	5m	1.2	2	1.5	1.1	1.4	1.9	1.3	1.4	1.9	1.2	1.6	2	1.2	1.5	2
14.	5n	R	R	R	1.1	1.3	1.7	1.1	1.3	1.6	R	R	R	1.1	1.4	1.8
15.	5o	1.4	1.6	2	1	1.2	1.4	R	R	R	1.1	1.2	1.5	1.2	1.5	2
16.	A	1.8			1.8			1.9			1.9			-		
17.	CPD	2.2			2.1			2.1			2.2			-		
18.	GF	1.8			1.9			2.0			2.0			-		
19.	GRF	-			-			-			-			2.6		
20.	FLC	-			-			-			-			2.8		

Note: Zone of inhibition interpretation is as follows.

1. ZONE SIZE < 1.0 C.M. – RESISTENT(R)
2. ZONE SIZE 1.0 To 1.5 – INTERMEDIATE
3. ZONE SIZE > 1.5 – SENSITIVE

STD Antibiotic Sensitivity Assay Concentration 40 µg/ml

A: AMPICILLIN
 CPD: CEFPODOXIME
 GF: GATIFLOXACIN
 GRF: GRESIOFULVIN
 FLC: FLUCONAZOLE

5. CONCLUSIONS

In summary, we have described the synthesis of 1,2,4-triazolo[1,5-*a*]pyrimidines derivatives in excellent yields. The reaction of *N*-cyclohexyl-4-methyl-3-oxo-pentanamide (**1**) with appropriate aldehyde (**2**) and aminoazole (**3**) was refluxed in DMF affords the *N*-cyclohexyl-4,7-dihydro-5-isopropyl-7-phenyl-[1,2,4]triazolo[1,5-*a*]pyrimidine-6-carboxamide derivatives was obtained in excellent yield. All the synthesized compounds are evaluated for their antimicrobial activity. The investigation of antibacterial and antifungal screening data revealed that all the tested compounds **5a-o** showed moderate to potent activity. The compounds **5j** and **5l** showed comparatively good activity against all the bacterial strains.

ACKNOWLEDGEMENT

Author thankful to Department of Chemistry, Saurashtra University for providing facilities and SAIF, Punjab University for instrumental support.

References

- [1] N. Zhang, A. Semiramis, N. Thai, *J. Med. Chem.* 50 (2007) 319.
- [2] L. Havlicek, K. Fuksova, V. Krystof, *Bioorg. Med. Chem.* 13 (2005) 5399.
- [3] M. Fraley, W. Hoffman, R. Rubino, *Bioorg. Med. Chem. Lett.* 12 (2002) 2767.
- [4] Q. Chen, X. Zhu, Z. Liu, *Eur. J. Med. Chem.* 43 (2008) 595.
- [5] S. Uryu, S. Tokuhira; T. Murasugi, *Brain Research* 946 (2002) 298.
- [6] L. Havlicek; K. Fuksova, V. Krystof, *Bioorg. Med. Chem.* 13 (2005) 5399
- [7] I. Drizin, M. Holladay, L. Yi, H. Zhangm, S. Gopalakrishnan, M. Gopalakrishnan, K. Whiteaker, S. Buckner, J. Sullivan, W. Carrol, *Bioorg. Med. Chem. Lett.* 12 (2002) 1481.
- [8] O. Fedorova, M. Zhidovinova, G. Rusinov, I. Ovchinnikova, *IzV. Akad. Nauk. Ser. Khim* (2003) 1677.
- [9] M. Pryadeina, Y. Burgart, V. Saloutin, M. Kodess, E. Ulomsky, V. Rusinov, *Zh. Org. Khim.* 40 (2004) 938.
- [10] V. Lipson, S. Desenko, M. Shirobokova, Borodina, *Chem. Heterocycl. Compd.* 39 (2003) 1213.
- [11] V. Lipson, S. Desenko, S. Shishkina, M. Shirobokova, O. Shishkin. V. Orlov, *Khim. Geterotsikl. Soedin.* 39 (2003) 1194.
- [12] G. Thirunarayanan, *International Letters of Chemistry, Physics and Astronomy* 5 (2014) 89-98.
- [13] Nirav M. Shah, Hitendra S. Joshi, *International Letters of Chemistry, Physics and Astronomy* 6 (2014) 56-60.
- [14] Piyush B. Vekariya, Jalpa R. Pandya, Vaishali Goswami, Hitendra S. Joshi, *International Letters of Chemistry, Physics and Astronomy* 7 (2014) 45-52.
- [15] Sagar P. Gami, Kalpesh V. Vilapara, Hasmukh R. Khunt, Jayesh S. Babariya, Yogesh T. Naliapara, *International Letters of Chemistry, Physics and Astronomy* 11(2) (2014) 127-134.

(Received 12 March 2014; accepted 19 March 2014)